动脉粥样硬化性心血管疾病的强化LDL胆固醇目标治疗
该开放标签优势试验在韩国纳入3048例动脉粥样硬化性心血管疾病患者,1:1随机分配至LDL胆固醇目标低于55 mg/dL(强化目标组)或低于70 mg/dL(常规目标组)。主要终点为3年内心血管原因死亡、非致死性心肌梗死、非致死性卒中、任何血运重建或不稳定型心绞痛住院的复合终点。强化目标组主要终点事件累积发生率为6.6%,常规目标组为9.7%(HR 0.67;95%CI 0.52-0.86;P=0.002)。两组预设安全性终点发生率相似,仅强化目标组肌酐升高发生率较低。
要点
- 在动脉粥样硬化性心血管疾病患者中,目标LDL胆固醇低于55 mg/dL较低于70 mg/dL显著降低3年主要复合心血管终点(6.6% vs 9.7%;HR 0.67;95%CI 0.52-0.86;P=0.002)。
- 试验期间强化目标组中位LDL胆固醇为56 mg/dL(1.4 mmol/L),常规目标组为66 mg/dL(1.7 mmol/L)。
- 两组预设安全性终点发生率相似,仅强化目标组肌酐升高发生率较低。
- 中位随访3.0年,共3048例患者随机分组(强化目标组1526例,常规目标组1522例)。
适用人群与场景
- 动脉粥样硬化性心血管疾病患者,来自韩国,随机分组接受强化或常规LDL胆固醇目标治疗。
诊断标准与关键阈值
- 强化目标组:LDL胆固醇目标低于55 mg/dL(1.4 mmol/L);常规目标组:LDL胆固醇目标低于70 mg/dL(1.8 mmol/L)。
研究设计与关键结果
- 开放标签优势试验,在韩国随机分配3048例动脉粥样硬化性心血管疾病患者,1:1至LDL胆固醇目标低于55 mg/dL(强化目标组,1526例)或低于70 mg/dL(常规目标组,1522例),中位随访3.0年。
- 主要终点为3年内心血管原因死亡、非致死性心肌梗死、非致死性卒中、任何血运重建或不稳定型心绞痛住院的复合终点;强化目标组100例发生主要终点事件(Kaplan-Meier累积发生率6.6%),常规目标组147例(9.7%)(HR 0.67;95%CI 0.52-0.86;P=0.002)。
- 试验期间中位LDL胆固醇水平:强化目标组56 mg/dL(1.4 mmol/L),常规目标组66 mg/dL(1.7 mmol/L)。
- 预设安全性终点发生率两组相似,仅强化目标组肌酐升高发生率较低。
证据类型、等级与局限
- 证据类型:开放标签优势随机对照试验;局限:原文未报告局限性。
指南或共识出处
- Ez-PAVE,ClinicalTrials.gov注册号NCT04626973;由Cardiovascular Research Center和Yuhan资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease remains limited.
METHODS: In this open-label superiority trial conducted in South Korea, we randomly assigned patients with atherosclerotic cardiovascular disease in a 1:1 ratio to a target LDL cholesterol level of less than 55 mg per deciliter (1.4 mmol per liter) (intensive-targeting group) or less than 70 mg per deciliter (1.8 mmol per liter) (conventional-targeting group). The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable angina at 3 years. Safety was also assessed.
RESULTS: Of 3048 patients who underwent randomization, 1526 were assigned to the intensive-targeting group and 1522 to the conventional-targeting group. The median follow-up was 3.0 years. The median LDL cholesterol level during the trial was 56 mg per deciliter (1.4 mmol per liter) in the intensive-targeting group and 66 mg per deciliter (1.7 mmol per liter) in the conventional-targeting group. A primary end-point event occurred in 100 patients (Kaplan-Meier estimate of cumulative incidence, 6.6%) in the intensive-targeting group and in 147 patients (Kaplan-Meier estimate of cumulative incidence, 9.7%) in the conventional-targeting group (hazard ratio, 0.67; 95% confidence interval, 0.52 to 0.86; P = 0.002). The incidence of prespecified safety end points was similar in the two trial groups, except for a lower incidence of creatinine elevation in the intensive-targeting group.
CONCLUSIONS: Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level of less than 55 mg per deciliter resulted in a lower risk of cardiovascular events at 3 years than targeting a level of less than 70 mg per deciliter. (Funded by the Cardiovascular Research Center and Yuhan; Ez-PAVE ClinicalTrials.gov number, NCT04626973.).
参考来源
- Lee YJ, Lee SJ, Kim JW, et al. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med. 2026. PMID: 41910315. doi:10.1056/NEJMoa2600283
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。